Figure 2.
STING in situ vaccination is improved when combined with CpG, anti-OX40, or anti-GITR. (A) Six- to 8-week-old BALB/C mice were implanted with 5 × 106 A20 cells on both flanks. One tumor was used as injection site and the other was monitored for systemic effect. Mice were treated on days 6, 8, and 10 after tumor implantation with IT injection of 5 μg STINGa and/or IT injection of 5 μg CpG (B); SC injection of 8 μg anti-OX40 antibodies (C); SC injection of 50 μg anti-GITR antibodies (D); IT injection of 5 μg Resiquimod (E). These experiments were reproduced at least twice. Error bars are SEM. Shown data are 1 representative experiment with 10 mice per group. Statistical significance of tumor growth was calculated by 2-way ANOVA. ***P < .001.
